<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01778686</url>
  </required_header>
  <id_info>
    <org_study_id>2012-002056-16</org_study_id>
    <nct_id>NCT01778686</nct_id>
  </id_info>
  <brief_title>Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors</brief_title>
  <official_title>Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gitte Moos Knudsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The serotonin 2A (5-HT2A) receptor is the most abundant excitatory serotonin (5-HT,&#xD;
      5-hydroxytryptamine) receptor in the human brain, and multiple positron emission tomography&#xD;
      (PET) studies have investigated the 5-HT2A receptors in the human brain using antagonist&#xD;
      radioligands. However, the currently available antagonist PET radioligands bind the total&#xD;
      pool of 5-HT2A receptor receptors whereas a 5-HT2A receptor agonist binds the high-affinity&#xD;
      subgroup of the receptors which are also G-protein coupled, and thus hypothesized to be the&#xD;
      functional relevant population of receptors. At the Center for Integrated Molecular Brain&#xD;
      Imaging (CIMBI), a novel agonist PET radioligands for brain imaging of 5-HT2A receptors was&#xD;
      recently validated in animals (Ettrup et al. 2011, EJNMMI). In the human brain, [11C]Cimbi-36&#xD;
      was validated as a selective 5-HT2A receptor agonist PET radioligand through a blocking study&#xD;
      with the 5-HT2A receptor antagonist pharmaceutical ketanserin. In this validation study, the&#xD;
      biodistribution and kinetic modelling of [11C]Cimbi-36 binding in the human brain was also&#xD;
      validated. With these studies, investigators will test the most promising of these,&#xD;
      [11C]Cimbi-36, in clinical trials, where it will provide a novel method for detecting&#xD;
      dysfunction in the 5-HT system. The specific aim of this clinical trial is:&#xD;
&#xD;
      - To examine the effect of acute alterations in 5-HT levels on cerebral [11C]Cimbi-36 binding&#xD;
      in healthy volunteers who will be PET-scanned at baseline and after pharmacological or&#xD;
      dietary interventions that either increase or decrease cerebral 5-HT levels.&#xD;
&#xD;
      It is hypothesized that this novel agonist radioligand will provide both a more physiological&#xD;
      relevant measure of the 5-HT2A receptors and also reflect levels of cerebral 5-HT in humans,&#xD;
      more specifically:&#xD;
&#xD;
      BP will decrease after pindolol and selective serotonin reuptake inhibitor (SSRI) treatment&#xD;
      and increase after acute tryptophan depletion (ATD). Placebo will leave binding potential&#xD;
      (BP) unchanged.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cerebral Cimbi-36 receptor binding in terms of binding potential (BP) at (1) baseline (2)acute tryptophan depletion (3) acute SSRI and pindolol (4) placebo</measure>
    <time_frame>2 hours</time_frame>
    <description>Cerebral Cimbi-36 receptor binding is measured with PET scanning for 2 hours. The resultant time-activity curves for brain tissue are used together with time-activity curves obtained with blood samples and kinetic modelling to yield unitless values of BP.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Citalopram and Pindolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Citalopram intravenous infusion starting 30 min before scanning, 40 mg/h for 1 hour.&#xD;
Pindolol peroral administration starting 3 days before scanning:&#xD;
Day 1: 2.5 mg 3 times daily, day 2: 5 mg 3 times daily, day 3: 7.5 mg 3 times daily, Day 4 (scan day) 7.5 mg morning and noon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for pindolol: sugar tablets that resembles pindolol&#xD;
Placebo for ATD: amino acid drink balanced formula (containing tryptophan)&#xD;
Placebo for Seropram: NaCl infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute tryptophan depletion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amino acid drink without tryptophan. Ingested 4-5 hours prior to PET scanning.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram and Pindolol</intervention_name>
    <description>Citalopram: selective serotonin reuptake inhibitor&#xD;
Pindolol: non-selective beta blocker and 5-HT1A receptor antagonist</description>
    <arm_group_label>Citalopram and Pindolol</arm_group_label>
    <other_name>Seropram</other_name>
    <other_name>HexapindolÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>On the second PET scanning day, subjects received a protein drink as well as a 50 ml saline infusion over 1 hour starting 30 min before PET scanning.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Acute tryptophan depletion</intervention_name>
    <arm_group_label>Acute tryptophan depletion</arm_group_label>
    <other_name>Amino acid drink without tryptophan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Generally healthy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  primary psychiatric disorder&#xD;
&#xD;
          -  current or previous neurological disease, severe somatic disease or taking medications&#xD;
             that can influence the results.&#xD;
&#xD;
          -  non-fluent in danish or severe visual or hearing impairment&#xD;
&#xD;
          -  current or previous learning difficulties&#xD;
&#xD;
          -  pregnancy or lactating&#xD;
&#xD;
          -  contraindications for magnetic resonance scanning&#xD;
&#xD;
          -  alcohol or drug abuse&#xD;
&#xD;
          -  allergy to any of the used medications&#xD;
&#xD;
          -  participation in studies with radioactivity (&gt;10 mSv) within the last year or&#xD;
             significant occupational exposure to radioactivity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Neurobiology Research Unit, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Ettrup A, Hansen M, Santini MA, Paine J, Gillings N, Palner M, Lehel S, Herth MM, Madsen J, Kristensen J, Begtrup M, Knudsen GM. Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers. Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):681-93. doi: 10.1007/s00259-010-1686-8. Epub 2010 Dec 21.</citation>
    <PMID>21174090</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>January 11, 2013</study_first_submitted>
  <study_first_submitted_qc>January 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2013</study_first_posted>
  <last_update_submitted>October 28, 2015</last_update_submitted>
  <last_update_submitted_qc>October 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Gitte Moos Knudsen</investigator_full_name>
    <investigator_title>Professor, DMSc</investigator_title>
  </responsible_party>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>Serotonin</keyword>
  <keyword>5-HT2A</keyword>
  <keyword>Radioligand</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pindolol</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Tryptophan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

